Cognition or genetics? Predicting Alzheimer's disease with practice effects, APOE genotype, and brain metabolism

Please use this identifier to cite or link to this item:
Información del item - Informació de l'item - Item information
Title: Cognition or genetics? Predicting Alzheimer's disease with practice effects, APOE genotype, and brain metabolism
Authors: Oltra-Cucarella, Javier | Sánchez San Segundo, Miriam | Ferrer-Cascales, Rosario | Alzheimer's Disease Neuroimaging Initiative
Research Group/s: Psicología Aplicada a la Salud y Comportamiento Humano (PSYBHE)
Center, Department or Service: Universidad de Alicante. Departamento de Psicología de la Salud
Keywords: Alzheimer's disease | Cognitive impairment | Dementia | Mild cognitive impairment | Neurodegenerative | Practice effects
Knowledge Area: Personalidad, Evaluación y Tratamiento Psicológico
Issue Date: Nov-2018
Publisher: Elsevier
Citation: Neurobiology of Aging. 2018, 71: 234-240. doi:10.1016/j.neurobiolaging.2018.08.004
Abstract: As practice effects are common in neuropsychological assessment, this study analyzed their utility to identify individuals with amnestic mild cognitive impairment (aMCI) at the greatest risk for Alzheimer's disease (AD-risk) and compared practice effects with APOE and brain metabolism biomarkers. We regressed Auditory Verbal Learning Test delayed recall (AVLT-DR) at 6 months on baseline AVLT-DR scores in 394 individuals with normal cognition from the Alzheimer's Disease Neuroimaging Initiative database and dichotomized 816 individuals with aMCI as showing practice effect or not showing practice effects (PE−) when the discrepancy between observed and predicted scores was found in less than 10%, 7%, and 5% of normal cognition. Cox regressions analyzed the AD-risk at 6 years. More than 60% of aMCI were showing practice effects. Controlling for age, sex, education, and baseline Mini-Mental State Examination and AVLT-DR scores, the AD-risk was associated with PE− [hazard ratio (HR) = 1.93], lower brain metabolism (HR = 0.95), and APOE genotype (HR = 1.92), with narrower risk estimates for PE−. The lack of practice effects during a 6-month period might be as precise as biomarkers for predicting the 6-year AD-risk.
Sponsor: Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012).
ISSN: 0197-4580 (Print) | 1558-1497 (Online)
DOI: 10.1016/j.neurobiolaging.2018.08.004
Language: eng
Type: info:eu-repo/semantics/article
Rights: © 2018 Elsevier Inc.
Peer Review: si
Publisher version:
Appears in Collections:INV - PSYBHE - Artículos de Revistas

Files in This Item:
Files in This Item:
File Description SizeFormat 
Thumbnail2018_Oltra-Cucarella_etal_NeurobioAging_final.pdfVersión final (acceso restringido)303,17 kBAdobe PDFOpen    Request a copy
Thumbnail2018_Oltra-Cucarella_etal_NeurobioAging_accepted.pdfAccepted Manuscript (acceso abierto)593,47 kBAdobe PDFOpen Preview

Items in RUA are protected by copyright, with all rights reserved, unless otherwise indicated.